Pre–commercial procurement to buy R&D services in the form of tools for modelling and dynamic assessment of integrated health and care pathways enhancing response capabilities

Participation in the open market consultation that was held in June to September 2023 as part of the preparation for this procurement is not a prerequisite for submitting a tender. This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs. Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation. The open procedure was chosen in Section IV.1.1) ‘Procedure’ for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures. Offers shall be submitted in English. All communication (before, during and after the procurement) can be made in English. More information See:

− the project website (https://dynamo-pcp.eu/) − the open market consultation recordings and slide decks (https://dynamo-pcp.eu/omc/) − FAQs (https://dynamo-pcp.eu/faq/) − PCPs on the Europa website (https://digital-strategy.ec.europa.eu/en/policies/innovation-procurement) or contact:

− suppliers@dynamo-pcp.eu

This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for a similar solution (so-called ‘Buyers Group’). The common challenge to be solved by R&D providers by designing, developing, and testing an integrated tool that supports the modelling and dynamic assessment of integrated health and care pathways enhancing response capacity of health systems. The tool should effectively support service planning in times of crisis by enabling:

1. the dynamic adaptation of service delivery processes to shocks and structural changes;

2. an ex-ante impact assessment of alternative service pathways according to relevant, definable parameters;

3. task planning and skills matching in times of crises. The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions from different suppliers. Each selected R&D provider will be awarded a framework agreement that covers three R&D phases. Each selected R&D provider will be awarded a framework agreement that covers the following R&D phases and a specific contract per phase:

1) Solution design,

2) Prototype development,

3) Original development and validation and testing of a limited volume of first products or services. After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. Testing in Phase 3 is expected to take place in Treviso (Italy), Olsztyński (Poland), Barcelona (Spain), Amadora (Portugal), West Wales (UK). This testing may also serve as a first customer test reference for the contractors. Phase 3 is expected to start in August 2025 and end in January 2026. The selected R&D providers will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions, i.e. beyond the procurement.